Ribomic Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Ribomic şirketinin toplam hissedar öz sermayesi ¥3.3B ve toplam borcu ¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥3.4B ve ¥109.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

JP¥0

Borç

Faiz karşılama oranı	n/a
Nakit	JP¥3.26b
Eşitlik	JP¥3.29b
Toplam yükümlülükler	JP¥109.00m
Toplam varlıklar	JP¥3.39b

Son finansal sağlık güncellemeleri

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

Oct 30

We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Jul 02

Recent updates

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

Oct 30

We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Jul 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4591 'nin kısa vadeli varlıkları ( ¥3.4B ) kısa vadeli yükümlülüklerini ( ¥108.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4591 şirketinin kısa vadeli varlıkları ( ¥3.4B ) uzun vadeli yükümlülüklerini ( ¥1,000.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4591 borçsuzdur.

Borcun Azaltılması: 4591 şirketinin 5 yıl önce borç/öz sermaye oranı 9.4% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4591 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 4591 serbest nakit akışı her yıl % 7.6 2.7 yıl yetecek nakit akışına sahip olacaktır.

Ribomic Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Recent updates

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

Ribomic Inc. to Report Q2, 2025 Results on Nov 12, 2024

Ribomic Inc. Announces Completion of Patient Enrollment in Early Phase Ii Study of Umedaptanib Pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase Ii Clinical Study

We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Ribomic Inc. to Report Q1, 2025 Results on Aug 09, 2024

New minor risk - Shareholder dilution

Ribomic Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Ribomic Inc. to Report Fiscal Year 2024 Results on May 14, 2024

Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.

Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.

Ribomic Inc. to Report Q3, 2024 Results on Feb 13, 2024

RIBOMIC Phase I and II Data Published in the Eye

First half 2024 earnings released

Ribomic Inc. to Report Q2, 2024 Results on Nov 13, 2023

New minor risk - Share price stability

First quarter 2024 earnings released

Ribomic Inc. to Report Q1, 2024 Results on Aug 10, 2023

Ribomic Inc., Annual General Meeting, Jun 27, 2023

Full year 2023 earnings released

Third quarter 2023 earnings released: JP¥18.86 loss per share (vs JP¥12.37 loss in 3Q 2022)

Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023

Ribomic Inc. to Report Q3, 2023 Results on Feb 10, 2023

Ribomic Inc. Announces the First Case Registration of Observational Study for RBM-007 Early Phase2 Development Project in Achondroplasia Patients

Second quarter 2023 earnings released: JP¥9.28 loss per share (vs JP¥15.44 loss in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥9.28 loss per share (vs JP¥15.44 loss in 2Q 2022)

Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023

Ribomic Inc. announced that it expects to receive ¥5.1372 million in funding

Ribomic Inc. to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: JP¥21.46 loss per share (vs JP¥12.04 loss in 1Q 2022)

RIBOMIC Announces Publication of anti-TGF-ß1 Aptamer Data Demonstrating Enhancement of anti-cancer Drug Efficacy

Ribomic Inc. to Report Q1, 2023 Results on Aug 09, 2022

Full year 2022 earnings released: JP¥59.92 loss per share (vs JP¥46.16 loss in FY 2021)

Ribomic Inc., Annual General Meeting, Jun 28, 2022

Less than half of directors are independent

Ribomic Inc. Announces Completion of IND submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia

Ribomic Inc. to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Ribomic Inc. to Report Q3, 2022 Results on Feb 14, 2022

RIBOMIC Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration

Second quarter 2022 earnings released: JP¥15.44 loss per share (vs JP¥11.57 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥12.04 loss per share (vs JP¥13.82 loss in 1Q 2021)

Ribomic Inc. Completes Patient Enrollment of Its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (Tofu Study)

Ribomic Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in Treatment Naive Wet AMD Patients

Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022

Ribomic Inc. Announces Completion of Its Phase I Trial of RBM-007 for the Treatment of Achondroplasia

Full year 2021 earnings released: JP¥46.16 loss per share (vs JP¥53.62 loss in FY 2020)

Third quarter 2021 earnings released: JP¥9.49 loss per share (vs JP¥15.71 loss in 3Q 2020)

Ribomic Inc. and ASKA Pharmaceutical Co., Ltd. Announces Execution of A Multi-Year Joint Research and Development Agreement for Drug Discovery Research and Development

Ribomic Inc. Announces Completion of 50% of Enrollment of its Phase 2 Clinical Trial for Wet Age-Related Macular Degeneration (Tofu Study)

New 90-day low: JP¥352

Ribomic Inc. to Report Q1, 2021 Results on Aug 07, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin